Novel 9-Methylanthracene Derivatives as p53 Activators for the Treatment of Glioblastoma Multiforme.

Yuxin Feng, Yingjie Wang, Xiaoxue Li, Ziqiang Sun, Sihan Qiang, Hongbo Wang, Yi Liu

Abstract read

In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yuxin FengKey Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Yantai University, Yantai 264005, China.

Yingjie WangKey Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Yantai University, Yantai 264005, China.

Xiaoxue LiSchool of Chemistry and Chemical Engineering, Yantai University, Yantai 264005, China.

Ziqiang SunSchool of Chemistry and Chemical Engineering, Yantai University, Yantai 264005, China.

Sihan QiangSchool of Chemistry and Chemical Engineering, Yantai University, Yantai 264005, China.

Hongbo WangKey Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Yantai University, Yantai 264005, China.ORCID 0000-0001-8530-2339

Yi LiuSchool of Chemistry and Chemical Engineering, Yantai University, Yantai 264005, China.ORCID 0000-0003-1513-8638

Funding

National Natural Science Foundation of China 82073888National Natural Science Foundation of China 82273969Shandong Provincial Natural Science Foundation ZR2020MB105Taishan Scholar Project tsqn202211112

6 · The paper itself

Abstract

Glioblastoma multiforme, a highly aggressive and lethal brain tumor, is a substantial clinical challenge and a focus of increasing concern globally. Hematological toxicity and drug resistance of first-line drugs underscore the necessity for new anti-glioma drug development. Here, 43 anthracenyl skeleton compounds as p53 activator

Indexed as

AnthracenesAntineoplastic AgentsBrain NeoplasmsGlioblastomaTumor Suppressor Protein p53ApoptosisCell Cycle ProteinsCell Line, TumorCell ProliferationHumansProto-Oncogene ProteinsAnthracenesAntineoplastic AgentsCell Cycle ProteinsMDM4 protein, humanProto-Oncogene ProteinsTP53 protein, humanTumor Suppressor Protein p53anthracenyl skeletonantiproliferativeglioblastoma multiformeMDM4p53

Identifiers

PMID38792257

DOI10.3390/molecules29102396

PMCPMC11123991

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.